If you can’t prevent cancer, the best chances of treating or surviving it may come down to finding a tumor early when it hasn’t yet spread. A new test called Cancerguard offers to screen for more than ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Cancerguard detects multiple cancers early by identifying specific DNA and protein markers in a blood sample. The test is available for adults aged 50-84 without cancer in the past three years, but it ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

Exact Sciences Corp. rolled out its multi-cancer early detection test nationwide to expand screening and identify malignancies when treatment has the greatest chance of being curative. Cancerguard can ...

Nearly 70 percent of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening.1,2,3 The Cancerguard test can help address the unmet need by complementing existing ...

Exact Sciences Corporation EXAS has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States.